In a nutshell This study aimed to investigate outcomes of salvage therapy after treatment with fludarabine, cyclophosphamidine and rituximab fails in patients with chronic lymphocytic leukemia. This study concluded that salvage therapy can provide excellent outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Evaluating venetoclax with BR for the treatment of relapsed or refractory non-Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read MoreComparing targeted therapy to chemotherapy for patients with advanced NSCLC
In a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...
Read MoreUmbilical cord blood transplantation for Hodgkin’s lymphoma
In a nutshell This study investigated the outcomes of umbilical cord blood transplantation in pretreated patients with Hodgkin’s lymphoma. The authors concluded that this procedure is a feasible treatment option for these patients. Some background Patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma have...
Read MoreNew targeted therapies for relapsed or refractory mantle cell lymphoma
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read MoreNew targeted therapies for relapsed or refractory mantle cell lymphoma
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read MoreVenetoclax for patients with relapsed/refractory chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the safety of venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax is safe in these patients as a long-term continuous therapy. Some background Venetoclax is a treatment used for patients with relapsed/refractory (RR)...
Read MoreBrentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.
In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...
Read MoreIs busulfan a useful drug to improve successful transplantation in the treatment of acute leukemia?
In a nutshell This study looked at the effect of using busulfan to delete blood cancer cells from the system before replacing them with normal cells in the treatment of leukaemia. The study found that busulfan therapy was effective in removing blood cancer cells before replacement, in the treatment of high-risk acute leukaemia. Some background Acute...
Read MoreLenalidomide and dexamethasone in relapsed/refractory multiple myeloma
In a nutshell This study examined the effect of lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma. This study concluded that the treatment combination was effective and results were similar to that seen in clinical trials. Some background Lenalidomide is a type of immunotherapy (stimulates the immune system to fight...
Read MoreWhat are the effects of treatment with brentuximab vedotin plus bendamustine on unresponsive HL?
In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...
Read MoreDoes ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read More
